Tech Transfer eNews Blog

U of Louisville personalized medicine start-up acquired for $15M

By Jesse Schwartz
Published: October 28th, 2020

A start-up from the University of Louisville (UofL) that helps patients with pancreatitis and other conditions has been acquired by biotech company Orgenesis in a roughly $15M deal.

Launched in 2016, Koligo Therapeutics uses patients’ own cells to develop personalized therapies. The start-up’s pancreatitis therapy is already on the market, and another for COVID-19-related acute respiratory distress will soon enter a multi-site Phase II clinical trial led by UofL.

“These therapies have come a long way since that first ‘eureka’ moment in the lab at UofL,” says Stuart K. Williams II, co-founder and chief technology officer at Koligo. “This acquisition supports expanded treatment of chronic pancreatitis patients and could further our cell-based treatments for COVID-19 patients throughout the United States.”

The UofL Commercialization EPI-Center, the university’s tech transfer arm, licensed the technology to Koligo and also maintains an equity stake in the start-up, which has become an equity stake in Orgenesis through the acquisition.

“We look forward to continuing our strong relationship with UofL, now with an even wider reach and global scale,” says Koligo CEO Matthew Lehman. “Together, Orgenesis and UofL will further develop these therapies that have real potential to save lives.”

Source: U of L News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment